Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358915 | 0.84 | — | — | |
| SCHEMBL17044584 | 0.82 | — | — | |
| SCHEMBL4751698 | 0.78 | — | — | |
| SCHEMBL5102499 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL17044633 | 0.75 | — | — | |
| SCHEMBL5606635 | 0.75 | — | — | |
| SCHEMBL7502214 | 0.73 | — | — | |
| SCHEMBL21522980 | 0.73 | — | — | |
| SCHEMBL1634949 | 0.73 | — | — | |
| SCHEMBL7247343 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0373600-B1 | Rust and corrosion preventive compounds | IDEMITSU KOSAN CO (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5223164-A | Additives for antifreezes, aqueous heat exchangers or hydraulic fluids | IDEMITSU KOSAN CO., LTD. (JP) | 1993-06-29 | — | — | US | claimed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-3908601-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Omeros Corporation (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2020-09-03 | — | — | US | disclosed |
| CN-111479795-A | Process for preparing ethers of cycloaliphatic or araliphatic diols | 巴斯夫欧洲公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2020146795-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-0373600-B1 | Rust and corrosion preventive compounds | IDEMITSU KOSAN CO (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5223164-A | Additives for antifreezes, aqueous heat exchangers or hydraulic fluids | IDEMITSU KOSAN CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0373600-A1 | Rust and corrosion preventive compounds | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | ALDH1A1 2936/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ALDH1A1 649/4885 |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | ALDH1A1 2936/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | ALDH1A1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.